MediWound to Host Second Quarter 2016 Financial Results Conference Call on July 28, 2016 at 8:30 a.m. Eastern Time
July 21 2016 - 8:00AM
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical
company bringing innovative therapies to address unmet needs in
severe burn and wound management, today announces that the Company
will release financial results for the three and six months ended
June 30, 2016, at 7:00 a.m. Eastern time on July 28, 2016.
Following the release, MediWound's management
will host a conference call for the investment community beginning
at 8:30 a.m. ET on Thursday, July 28, 2016, to discuss the
financial results and to answer questions.
Shareholders and other interested parties may
participate in the conference call by dialing (877) 602-7189
(domestic) or (678) 894-3057 (international) and entering passcode
45894739. The call also will be broadcast live on the Internet on
the Company’s website at www.mediwound.com.
A replay of the call will be accessible two
hours after its completion through August 4, 2016 by dialing (855)
859-2056 (domestic) or (404) 537-3406 (international) and entering
passcode 45894739. The call will also be archived on the Company
website for 90 days at www.mediwound.com.
About MediWound Ltd.MediWound
is a fully-integrated biopharmaceutical company focused on
developing, manufacturing and commercializing novel therapeutics
based on its patented proteolytic enzyme technology to address
unmet needs in the fields of severe burns, chronic and other
hard-to-heal wounds. MediWound’s first innovative biopharmaceutical
product, NexoBrid®, received marketing authorization from the
European Medicines Agency as well as the Israeli and Argentinian
Ministries of Health, for removal of dead or damaged tissue, known
as eschar, in adults with deep partial and full-thickness thermal
burns and was launched in Europe, Israel, and Argentina.
NexoBrid represents a new paradigm in burn care management,
and clinical trials have demonstrated, with statistical
significance, its ability to non-surgically and rapidly remove the
eschar earlier and without harming viable tissue.
MediWound's second innovative product,
EscharEx®, is a topical biological drug being developed for
debridement of chronic and other hard-to-heal wounds and is
complementary to the large number of existing wound healing
products, which require a clean wound bed in order to heal the
wound. EscharEx contains the same proteolytic enzyme technology as
NexoBrid, and benefits from the wealth of existing development data
on NexoBrid. In two Phase 2 studies, EscharEx demonstrated
safety and efficacy in the debridement of chronic and other
hard-to-heal wounds, within a few daily applications.
For more information, please visit
www.mediwound.com.
|
|
|
|
|
|
Contacts: |
|
|
|
|
Anne Marie Fields |
Sharon Malka |
|
|
|
|
Senior Vice President |
Chief Financial and Operations Officer |
|
|
|
|
LHA |
MediWound |
|
|
|
|
212-838-3777 |
ir@mediwound.co.il |
|
|
|
|
afields@lhai.com |
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From Apr 2023 to Apr 2024